Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Want to see ABEO full AI Analyst Report?
ABEO Stock Chart & Stats
$5.50
-$0.15(-2.50%)
At close: 4:00 PM EST
$5.50
-$0.15(-2.50%)
Day’s Range― - ―
52-Week Range$4.00 - $7.54
Previous CloseN/A
Volume71.38K
Average Volume (3M)1.38M
Market Cap
$339.44M
Enterprise Value$279.13M
Total Cash (Recent Filing)$191.40M
Total Debt (Recent Filing)$24.97M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 13, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding57,049,023
10 Day Avg. Volume1,211,235
30 Day Avg. Volume1,378,843
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue47.96
Enterprise Value/Gross Profit182.20
Enterprise Value/Ebitda-3.25
Forecast
1Y Price Target
$21.40Price Target Upside289.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.73
Revenue Forecast (FY)$65.61M
Bulls Say, Bears Say
Bulls Say
Commercial Rollout ProgressInitial patient treatments and ongoing biopsies for ZEVASKYN show the program is moving from clinical development toward real-world delivery, supporting early commercial momentum.
Market Access And ReimbursementPublished coverage policies from major commercial insurers and Medicaid for ZEVASKYN reduce reimbursement barriers and improve the therapy's ability to reach eligible patients.
Regulatory Approval UpsideA licensee resubmission for UX111 that includes expanded clinical and biomarker data, combined with analyst models currently excluding UX111, suggests approval could create meaningful upside to forecasts and royalty prospects.
Bears Say
Demand-to-revenue Conversion RiskHealthy patient demand may not translate into immediate revenue if production throughput remains restricted, risking slower-than-expected sales growth.
Manufacturing Capacity ConstraintCurrent manufacturing capacity supports only a limited number of patients per month, which could constrain near-term commercial momentum and patient throughput.
Manufacturing Scale-up And Financing RiskExpanding manufacturing to meet demand may require significant capital and operational execution, introducing risks to financial flexibility and rollout timing.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $4.00 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $339.44M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 7 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Mar 17, 2026. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.008.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 57,049,023 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went down -3.838%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.40 (289.09% Upside)
$21.40 (289.09% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.63%
12-Months-Change
Fundamentals
Return on Equity
53.18%
Trailing 12-Months
Asset Growth
103.04%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
ABEO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted several strong positives: a transformative one-time gain from the priority review voucher that produced a substantial net income swing and strengthened cash; regulatory and reimbursement progress (J-code and broad payer coverage); growing patient identification (50 to +100); and an on-track manufacturing capacity expansion to ~10 patients/month. However, meaningful operational risks and near-term commercialization challenges remain: an earlier sterility-related batch failure and launch delay, slow initial patient throughput (only two treated to date), a lengthy 4–5 month timeline from consult to treatment, and sharply higher SG&A as the company transitions to commercial operations. While early commercial traction is improving and the company has sufficient liquidity, execution of QTC onboarding and consistent patient cadence are critical to meet profitability and scale expectations.View all ABEO earnings summariesABEO Stock 12 Month Forecast
Average Price Target
$21.40
▲(289.09% Upside)
Technical Analysis
Ownership Overview
6.85% Insiders
6.69% Mutual Funds
8.09% Other Institutional Investors
69.48% Public Companies and
Individual Investors